Oral and otolaryngological complications of radiotherapy for head and neck cancers among patients attending Ocean Road Cancer Institute, Tanzania

  • Benedict Ngunyale Mbeya Zonal Referral Hospital
  • Zephania Saitabau Abraham University of Dodoma, College of Health Sciences
  • Enica Richard Massawe Muhimbili University of Health and Allied Sciences
  • Daudi Ntunaguzi Muhimbili University of Health and Allied Sciences
  • Bonaventura Mpondo University of Dodoma, College of Health Sciences



The prevalence of head and neck cancers is on the increase worldwide. Treatment modalities include surgery, radiotherapy and chemotherapy. The aim of this study was to determine the proportion of acute oral and otolaryngological complications of radiotherapy with or without chemotherapy for head and neck cancers.


A retrospective cross-sectional, hospital based study was done to 80 patients with head and neck cancers who have just completed radiotherapy with or without chemotherapy at Ocean Road Cancer Institute (ORCI). Data was collected using a structured questionnaire within one week after completion of radiotherapy.  Patients who reported hearing loss underwent otoscopy and audio-logical assessment including tympanometry and pure tone audiometry. Data was analyzed using SPSS program.


The proportion of males was higher than that of females in the ratio of 2:1 and majority of the patients involved were in the 6th decade of life, (27.5%). Out of the 80 study participants, 80% were found to have oropharyngeal mucositis, 90% were found to have xerostomia and 50% were found to have dysphagia. In addition, 76.2% of patients reported to have developed taste disorders after radiotherapy and 43.1% reported to have developed voice disorders. The proportion of hearing loss following radiotherapy was 21.9% though this should be taken with caution since there was no before and after intervention taken. Patients with sinonasal cancers had the least proportion of oral and oropharyngeal mucositis (50%), xerostomia (64.3%) and voice disorders (14.3%). Most of patients who developed hearing loss had nasopharyngeal cancer (85.6%) and salivary gland cancer (66.7%) while patients with oropharyngeal cancer, hypopharyngeal cancer and laryngeal cancer did not develop hearing loss at all.


Oral and otolaryngological complications of radiotherapy with or without chemotherapy for head and neck cancers at ORCI are quite prevalent. Prevention of complications should be highly regarded especially by using shield protectors on uninvolved areas and advanced radiotherapy machines should be considered to minimize such complications.

Key words: Oral, otolaryngological, head, neck, cancers, Tanzania.

Author Biographies

Benedict Ngunyale, Mbeya Zonal Referral Hospital
ENT Surgeon, Department of Otorhinolaryngology
Zephania Saitabau Abraham, University of Dodoma, College of Health Sciences
Tutorial Assistant, Department of Surgeons
Enica Richard Massawe, Muhimbili University of Health and Allied Sciences
Lecturer and Head, Department of Otorhinolaryngology
Daudi Ntunaguzi, Muhimbili University of Health and Allied Sciences
Lecturer, Department of Otorhinolaryngology
Bonaventura Mpondo, University of Dodoma, College of Health Sciences
Senior Lecturer, Department of Internal Medicine


Rose-Ped AM, Bellm LA, Epstein JB, Trotti A, Gwede C, Fuchs HJ. Complications of radiation therapy for head and neck cancers: the patient’s perspective. Cancer nursing. 2002 Dec 1;25(6):461-7.

Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nature Reviews. Clinical Oncology. 2007 Mar 1;4(3):156.

. Bhandare N, Mendenhall WM. A literature review of late complications of radiation therapy for head and neck cancers: incidence and dose response. J Nucl Med Radiat Ther S. 2012;2(009).

Supportive PD, Board PC. Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ®).

Nguyen NP, Abraham D, Desai A, Betz M, Davis R, Sroka T, Chi A, Gelumbauskas S, Ceizyk M, Smith-Raymond L, Stevie M. Impact of image-guided radiotherapy to reduce laryngeal edema following treatment for non-laryngeal and non-hypopharyngeal head and neck cancers. Oral oncology. 2011 Sep 30;47(9):900-4.

Fletcher G, America N, Eortc T, et al. Head and neck cancer. 2006;(June):4-6.

Tolentino ED, Centurion BS, Ferreira LH, Souza AP, Damante JH, Rubira-Bullen IR. Oral adverse effects of head and neck radiotherapy: literature review and suggestion of a clinical oral care guideline for irradiated patients. Journal of Applied Oral Science. 2011 Oct;19(5):448-54.

Rubin P, Constine LS, Marks LB. ALERT-Adverse Late Effects of Cancer Treatment. Springer; 2014 Dec 3.

Lazarus CL. Effects of chemoradiotherapy on voice and swallowing. Current opinion in otolaryngology & head and neck surgery. 2009 Jun;17(3):172.

Low WK, Rangabashyam M. Ear-related issues in patients with nasopharyngeal carcinoma. InCarcinogenesis, Diagnosis, and Molecular Targeted Treatment for Nasopharyngeal Carcinoma 2012. InTech.

Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. International Journal of Radiation Oncology* Biology* Physics. 2009 Mar 1;73(3):779-88.

van der Molen L, van Rossum MA, Jacobi I, van Son RJ, Smeele LE, Rasch CR, Hilgers FJ. Pre-and posttreatment voice and speech outcomes in patients with advanced head and neck cancer treated with chemoradiotherapy: expert listeners’ and patient’s perception. Journal of Voice. 2012 Sep 30;26(5):664-e25.

Dirix P, Nuyts S, Van den Bogaert W. Radiation‐induced xerostomia in patients with head and neck cancer. Cancer. 2006 Dec 1;107(11):2525-34.

Ridge JA, Mehra R, Lango MN, Galloway T, Pisters PW, Weiss M, Maki R, Raut CP, Povoski SP, McDonnell AM, Movsas B. ubmslateCN-logo-ubm. Oncology.;5(6):7.

Mwansasu C, Liyombo E, Moshi N, Mpondo BC. Pattern of head and neck cancers among patients attending Muhimbili National Hospital Tanzania. Tanzania Journal of Health Research. 2015;17(1).

Onyango JF, Awange DO, Njiru A, Macharia IM. Pattern of occurrence of head and neck cancer presenting at Kenyatta National Hospital, Nairobi. East African medical journal.2006 May;83(5):288

Goodwin WJ, Thomas GR, Parker DF, Joseph D, Levis S, Franzmann E, Anello C, Hu JJ. Unequal burden of head and neck cancer in the United States. Head & neck. 2008 Mar 1;30(3):358-71.

Solomon MM. Determination of acute complications of head neck radiotherapy their impact on treatment and quality of life. Dissertation, University of Nairobi;2014.

Szczesniak MM, Maclean J, Zhang T, Graham PH, Cook IJ. Persistent dysphagia after head and neck radiotherapy: a common and under-reported complication with significant effect on non-cancer-related mortality. Clinical Oncology. 2014 Nov 30;26(11):697-703.

Dirix P, Nuyts S, Vander Poorten V, Delaere P, Van den Bogaert W. The influence of xerostomia after radiotherapy on quality of life. Supportive Care in Cancer. 2008 Feb 1;16(2):171-9.

Hamdan AL, Geara F, Rameh C, Husseini ST, Eid T, Fuleihan N. Vocal changes following radiotherapy to the head and neck for non-laryngeal tumors. European Archives of Oto-Rhino-Laryngology. 2009 Sep 1;266(9):1435-9.

Vainshtein JM, Griffith KA, Feng FY, Vineberg KA, Chepeha DB, Eisbruch A. Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study. International Journal of Radiation Oncology* Biology* Physics. 2014 Aug 1;89(5):973-80.

Saluja M, Thakur J, Azad R, Sharma D, Mohindroo N, Seam R, Vasanthalakshmi M. Radiotherapy induced hearing loss in head neck cancers: screening with DPOAE. Head Neck Oncol. 2014;6(3):3.

Zhang XX, Ma L, Wang JL, Wu WM, Feng LC, Huang DL. Management of oral mucositis in patients with head and neck cancer receiving chemoradiotherapy and/or molecular targeted therapy. Zhonghua er bi yan hou tou jing wai ke za zhi= Chinese journal of otorhinolaryngology head and neck surgery. 2011 Jun;46(6):505-8.

Koukourakis MI, Danielidis V. Preventing radiation induced xerostomia. Cancer treatment reviews. 2005 Nov 30;31(7):546-54

Original Research